Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 121

1.

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.

Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL.

Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22.

PMID:
28019071
2.

Comparison of exposure response relationship of atrasentan between North American and Asian populations.

Heerspink HJ, Makino H, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Davis JW, Idler K, Kohan DE, Liu M, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2017 Apr;19(4):545-552. doi: 10.1111/dom.12851. Epub 2017 Jan 27.

PMID:
27981738
3.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ.

Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30.

PMID:
26229089
4.

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.

Kohan DE, Lambers Heerspink HJ, Coll B, Andress D, Brennan JJ, Kitzman DW, Correa-Rotter R, Makino H, Perkovic V, Hou FF, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1568-74. doi: 10.2215/CJN.00570115. Epub 2015 Jul 7.

5.

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.

Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):410-6. doi: 10.2215/CJN.07780814. Epub 2015 Jan 7.

6.

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH.

J Am Soc Nephrol. 2014 May;25(5):1083-93. doi: 10.1681/ASN.2013080830. Epub 2014 Apr 10.

7.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.

Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D.

Nephrol Dial Transplant. 2013 Sep;28(9):2260-8. doi: 10.1093/ndt/gft227. Epub 2013 Jun 19.

8.

Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.

Zager RA, Johnson AC, Andress D, Becker K.

Kidney Int. 2013 Oct;84(4):703-12. doi: 10.1038/ki.2013.157. Epub 2013 May 22.

9.

Reply to "The role of fibroblast growth factor-23 in left atrial volume".

Tamez H, Andress D, Solomon SD, Thadhani R.

Am Heart J. 2013 May;165(5):e23. doi: 10.1016/j.ahj.2013.02.023. Epub 2013 Mar 27. No abstract available.

PMID:
23622924
10.

Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.

Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R.

Am Heart J. 2012 Dec;164(6):902-9.e2. doi: 10.1016/j.ahj.2012.09.018. Epub 2012 Oct 29.

PMID:
23194491
11.

Impact of elevated intact parathyroid hormone on mortality and renal disease progression in patients with chronic kidney disease stages 3 and 4.

Asche CV, Marx SE, Kim J, Unni SK, Andress D.

Curr Med Res Opin. 2012 Sep;28(9):1527-36. Epub 2012 Aug 13.

PMID:
22834871
12.

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD.

JAMA. 2012 Feb 15;307(7):674-84. doi: 10.1001/jama.2012.120.

PMID:
22337679
13.

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).

Andress DL, Coll B, Pritchett Y, Brennan J, Molitch M, Kohan DE.

Life Sci. 2012 Oct 15;91(13-14):739-42. doi: 10.1016/j.lfs.2012.01.011. Epub 2012 Feb 2.

14.

Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.

Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S.

Am J Kidney Dis. 2012 Jan;59(1):58-66. doi: 10.1053/j.ajkd.2011.06.027. Epub 2011 Aug 31.

PMID:
21885174
15.

Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP).

McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, Vassalotti JA, Stevens LA, Salifu MO, Kurella Tamura M, Bomback AS, Norris KC, Collins AJ, Bakris GL, Whaley-Connell AT; KEEP Steering Committee.

Am J Kidney Dis. 2011 Mar;57(3 Suppl 2):S24-31. doi: 10.1053/j.ajkd.2010.11.009.

16.

Incident isolated 1,25(OH)(2)D(3) deficiency is more common than 25(OH)D deficiency in CKD.

Levin A, Le Barbier M, Er L, Andress D, Sigrist MK, Djurdjev O.

J Nephrol. 2012 Mar-Apr;25(2):204-10. doi: 10.5301/JN.2011.8429.

PMID:
21688248
17.

The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.

Pritchett Y, Jemiai Y, Chang Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata-Andía JB, Thompson T, Appelbaum E, Audhya P, Andress D, Zhang W, Solomon S, Manning WJ, Thadhani R.

Clin Trials. 2011 Apr;8(2):165-74. doi: 10.1177/1740774511399128.

PMID:
21478328
18.

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.

Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL.

J Am Soc Nephrol. 2011 Apr;22(4):763-72. doi: 10.1681/ASN.2010080869. Epub 2011 Mar 3.

19.

Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease.

Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD.

Am J Nephrol. 2011;33(2):139-49. doi: 10.1159/000323551. Epub 2011 Jan 18.

PMID:
21242674
20.

The use of SDS-PAGE scanning of spent dialysate to assess uraemic toxin removal by dialysis.

Ficheux A, Gayrard N, Szwarc I, Andress D, Soullier S, Duny Y, Goubert G, Thomas M, Bismuth-Mondolfo J, Daurès JP, Brunet P, Servel MF, Argilés A.

Nephrol Dial Transplant. 2011 Jul;26(7):2281-9. doi: 10.1093/ndt/gfq709. Epub 2010 Dec 10.

Supplemental Content

Loading ...
Support Center